Kristie L. Kahl is vice president of content at MJH Life Sciences, overseeing CURE®, CancerNetwork®, the journal ONCOLOGY, Targeted Oncology, and Urology Times®. She has been with the company since November 2017.
She is a graduate of Rider University, where she acquired a Bachelors of Art in journalism, as well as a graduate of Temple University, where she received her Masters of Science in Sports Management.
Follow Kristie on Twitter at @KristieLKahl, or email her at kkahl@mjhlifesciences.com.
FDA Approves Leukine to Treat Blood-Related Acute Radiation Syndrome
June 6th 2018The Food and Drug Administration (FDA) approved Leukine (sargramostim) for the treatment of adult and pediatric patients who are exposed to myelosuppressive doses of radiation that results in a hematopoietic subsyndrome of acute radiation syndrome.
Read More
FDA Approves First Biosimilar to Reduce Risk of Infection During Cancer Treatment
June 5th 2018The Food and Drug Administration (FDA) approved Fulphila (pegfilgrastim-jmdb) as the first biosimilar to Neulasta (pegfilgrastim) to reduce the risk for febrile neutropenia in patients treated with chemotherapy in certain types of cancer.
Read More
Immunotherapy Combination Shows Promise, Side Effects Ensue in Colorectal Cancer Subgroup
May 25th 2018Despite improved outcomes, the researchers also found that side effects with checkpoint inhibition often affected the dermatologic, gastrointestinal, pulmonary, renal, endocrine and hepatic systems in patients.
Read More
Navigating the Waves of Cancer Treatment
May 17th 2018In this week’s episode of CURE Talks Cancer, we spoke with Matt Lashey, creator and CEO of the chemoWave app, which is designed to manage cancer symptoms and conditions by keeping track of a patient’s overall well-being to understand how their experiences may be related to feeling better or worse during treatment.
Read More
FDA Approves Darzalex Combination for Newly Diagnosed Multiple Myeloma
May 8th 2018The Food and Drug Administration (FDA) granted approval to Darzalex (daratumumab) in combination with Velcade (bortezomib), melphalan and prednisone – also known as VMP – for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT).
Read More
Genetic Testing, Treatment Advances Offer 'Hope on the Horizon' for Ovarian Cancer
April 28th 2018During the 2018 National Ovarian Cancer Coalition, Angeles Alvarez Secord, M.D., MHSc highlighted the importance of genetic testing and its impact on treatment options for women with ovarian cancer.
Read More
High-Grade Endometrioid Endometrial Cancers Likely to Benefit from Immunotherapy
April 24th 2018Researchers evaluates microsatellite instability-high status, tumor mutation burden and high PD-L1 expression to determine which grade of tumors would benefit from immunotherapy treatment among women with endometrioid endometrial cancer.
Read More